MedTrace Logo

Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib

NCT05464173 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2024-01-22

No results posted yet for this study

Summary

To evaluate the efficacy and safety of chidamide in combination with abemaciclib and endocrinotherapy（doctor's choice） in locally advanced/metastatic HR+/HER2- breast cancer who had failed prior palbociclib therapy

Conditions

Interventions

DRUG

Chidamide

10-30mg biw

DRUG

Abemaciclib

150mg or 100mg bid

DRUG

endocrinotherapy（doctor's choice）

According to the drug insert

Sponsors & Collaborators

  • Biyun Wang, MD

    lead OTHER

Principal Investigators

  • Biyun Wang · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2025-02-01
Completion
2025-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05464173 on ClinicalTrials.gov